Streetbeat News

OCGN

Ocugen, Inc.

https://www.ocugen.com

Industry

Biotechnology

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Open

1.07

Mkt cap

311M

Volume

5.2M

High

1.10

P/E Ratio

-6.00

52-wk high

2.10

Low

1.04

Div yield

N/A

52-wk low

0.35

Ocugen's (NYSE:OCGN) short interest has risen by 15.83%, with 24.37% of its float sold short. This is significantly higher than its peers' average of 11.57%. It would take traders 11.68 days to cover their short positions.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 8:15 pm

Ocugen reported $16 million in cash, cash equivalents, and restricted cash as of June 30, 2024. The company also closed a public offering with net proceeds of $32.6 million, extending its cash runway into Q3 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:54 am

Ocugen reported its Q2 2024 financial results, with a GAAP EPS of $(0.04), beating the estimated $(0.06). The company also reported sales of $1.141 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:52 am

Ocugen has received notification from the FDA to begin its Expanded Access Program for treating adult patients with OCU400.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 10:31 am

Ocugen Inc (NASDAQ:OCGN) shares fell by 11% to $1.25 after announcing a public offering of 30,434,783 shares at $1.15 per share, aiming to raise $35 million. The offering includes a 30-day option for the underwriter to purchase an additional 4,565,217 shares. Proceeds will be used for general corporate purposes.

Portfolio Pulse from Henry Khederian

August 01, 2024 | 1:18 pm

Ocugen shares are trading lower after the company priced a 30,434,783 share offering at $1.15 per share.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:28 am

Ocugen has announced a public offering of $35 million, pricing 30,434,783 common shares at $1.15 per share.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 6:55 am

Ocugen shares are trading lower following the company's announcement of an underwritten public offering.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:08 pm

Ocugen has announced an underwritten public offering of its common stock, though the size of the offering has not been disclosed. The underwriter has been granted a 30-day option to purchase an additional 15% of shares. The offering is subject to market and other conditions.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 9:08 pm

Ocugen has completed dosing in the third cohort of its Phase 1/2 ArMaDa trial for OCU410 (AAV-hRORA) targeting geographic atrophy. The company has also initiated a Phase 2 trial to assess OCU410 in a larger group of patients.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 10:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.